Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor

被引:15
|
作者
Harper, ME
Goddard, L
Glynne-Jones, E
Assender, J
Dutkowski, CM
Barrow, D
Dewhurst, OL
Wakeling, AE
Nicholson, RI
机构
[1] Cardiff Univ, Welsh Sch Pharm, Tenovus Ctr Canc Res, Cardiff CF10 3XF, S Glam, Wales
[2] Astra Zeneca Pharmaceut, Macclesfield, Cheshire, England
来源
PROSTATE | 2002年 / 52卷 / 01期
关键词
prostate cell lines; tyrosine kinase inhibitor; EGF receptor; MAPK;
D O I
10.1002/pros.10069
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Epidermal growth factor receptor (EGF-R) autophosphorylation is essential for its intracellular mitogenic signaling via the MAPK pathway and for interaction in other cellular processes. Inhibition of this activity in tumor cells that predominantly utilise EGF-R therefore offers an alternative approach to therapy. METHODS. The ability of a specific inhibitor of EGF-R tyrosine kinase, ZM 252868, (TKI) to alter various parameters related to growth in DU145 and PC3 cell lines was investigated, by immunocytochemistry, Northern blotting, Western blotting and invasion assays. RESULTS. In DU145 cultures, the total cell population and number of cells in cell cycle decreased in the presence of TKI whilst the apoptotic rate was significantly increased. Reduction in autophosphorylation of the EGF-R, membrane expression of EGF-R, activation of the MAPK, p38, and JNK enzymes and the invasive capacity of DU145 cells was observed in the TKI treated cells. Under the same conditions, PC3 cell growth and EGF-R expression and MAPK activation were not affected. The use of inhibitors of intracellular signaling indicated that the DU145 cells, in contrast to PC3 cells, predominantly utilize EGF-R activation of the MAPK signaling pathway for growth. CONCLUSIONS. In prostatic cancer patients, in whom androgen resistance has developed and whose tumors have upregulated EGF-R for growth, specific TKI's may offer an important therapy option. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:59 / 68
页数:10
相关论文
共 50 条
  • [11] Preclinical analysis of the analinoquinazoline AG14781 a specific small molecule inhibitor of EGF receptor tyrosine kinase
    Ellis, AG
    Doherty, MM
    Walker, F
    Weinstock, J
    Nerrie, M
    Vitali, A
    Murphy, R
    Johns, TG
    Scott, AM
    Levitzki, A
    McLachlan, G
    Webster, LK
    Burgessc, AW
    Nicec, EC
    BIOCHEMICAL PHARMACOLOGY, 2006, 71 (10) : 1422 - 1434
  • [12] Increased activation of EGF-receptor tyrosine kinase by EGF and TGF-alpha in the colonic mucosa of aged rats
    MaleckaPanas, E
    Relan, NK
    Majumdar, APN
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 1996, 51 (01): : B60 - B65
  • [13] EGF receptor clustering is induced by a 0.4 mT power frequency magnetic field and blocked by the EGF receptor tyrosine kinase inhibitor PD153035
    Jia, Caili
    Zhou, Zhenjie
    Liu, Renchen
    Chen, Shude
    Xia, Ruohong
    BIOELECTROMAGNETICS, 2007, 28 (03) : 197 - 207
  • [14] Inhibition of EGF receptor tyrosine kinase activity by plant polyphenols
    Yang, EB
    Tang, WY
    Cheng, LY
    Mack, P
    FASEB JOURNAL, 1997, 11 (09): : A915 - A915
  • [15] DETERMINANTS OF INTERACTIONS BETWEEN THE EGF RECEPTOR TYROSINE KINASE AND SUBSTRATES
    KLINGBEIL, CK
    CADENA, DL
    GILL, GN
    FASEB JOURNAL, 1995, 9 (06): : A1305 - A1305
  • [16] EGF RECEPTOR TYROSINE KINASE IS ESSENTIAL FOR STIMULATION OF RAT CARDIAC ADENYLATE-CYCLASE BY EGF
    NAIR, BG
    PATEL, TB
    FASEB JOURNAL, 1991, 5 (05): : A1184 - A1184
  • [17] KINETIC-MODEL OF THE EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR TYROSINE KINASE AND A POSSIBLE MECHANISM OF ITS ACTIVATION BY EGF
    POSNER, I
    ENGEL, M
    LEVITZKI, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1992, 267 (29) : 20638 - 20647
  • [18] Versatility in signalling:: Multiple responses to EGF receptor activation during Drosophila oogenesis
    Van Buskirk, C
    Schüpbach, T
    TRENDS IN CELL BIOLOGY, 1999, 9 (01) : 1 - 4
  • [19] Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity
    Akhtar, S
    Dunnion, D
    Poyner, D
    Bibby, M
    Double, J
    BIOCHEMICAL PHARMACOLOGY, 2002, 63 (12) : 2187 - 2195
  • [20] Activation and inhibition of the EGF receptor
    Lemmon, MA
    FASEB JOURNAL, 2005, 19 (05): : A1690 - A1690